{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:09Z","timestamp":1788675429060,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"DOI":"10.7759\/cureus.109421","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:21:08Z","timestamp":1779452468000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Hyperammonemic Encephalopathy Associated With Gastrointestinal Bleeding During Capecitabine and Oxaliplatin Chemotherapy in a Patient With Rectal Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Taiga","family":"Komatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veevek Anand","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1600561","article-title":"Hepatic encephalopathy","volume":"375","author":"Wijdicks EF","year":"2016","unstructured":"Wijdicks EF. Hepatic encephalopathy. N Engl J Med. 2016, 375:1660-70. 10.1056\/NEJMra1600561","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00366-6","article-title":"Hepatic encephalopathy","volume":"8","author":"H\u00e4ussinger D","year":"2022","unstructured":"H\u00e4ussinger D, Dhiman RK, Felipo V, et al.. Hepatic encephalopathy. Nat Rev Dis Primers. 2022, 8:43. 10.1038\/s41572-022-00366-6","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03938.x","article-title":"Review article: hyperammonaemic and catabolic consequences of upper gastrointestinal bleeding in cirrhosis","volume":"29","author":"Olde Damink SW","year":"2009","unstructured":"Olde Damink SW, Dejong CH, Jalan R. Review article: hyperammonaemic and catabolic consequences of upper gastrointestinal bleeding in cirrhosis. Aliment Pharmacol Ther. 2009, 29:801-10. 10.1111\/j.1365-2036.2009.03938.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000987","article-title":"Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?","volume":"31","author":"Di Federico A","year":"2020","unstructured":"Di Federico A, Nuvola G, Sisi M, Lenzi B, Nobili E, Campana D. Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?. Anticancer Drugs. 2020, 31:1103-5. 10.1097\/CAD.0000000000000987","journal-title":"Anticancer Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006874","article-title":"Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: a case series and review of the literature","volume":"96","author":"Mitani S","year":"2017","unstructured":"Mitani S, Kadowaki S, Komori A, et al.. Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: a case series and review of the literature. Medicine (Baltimore). 2017, 96:e6874. 10.1097\/MD.0000000000006874","journal-title":"Medicine (Baltimore)"},{"key":"ref6","article-title":"Fluorouracil-induced hyperammonemia in a patient with colorectal cancer","volume":"35","author":"Thomas SA","year":"2015","unstructured":"Thomas SA, Tomeh N, Theard S. Fluorouracil-induced hyperammonemia in a patient with colorectal cancer. Anticancer Res. 2015, 35:6761-3.","journal-title":"Anticancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3249-1","article-title":"Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia","volume":"79","author":"Nishikawa Y","year":"2017","unstructured":"Nishikawa Y, Funakoshi T, Horimatsu T, et al.. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer Chemother Pharmacol. 2017, 79:629-33. 10.1007\/s00280-017-3249-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.019","article-title":"5-Fluorouracil-induced hyperammonaemic encephalopathy: a French national survey","volume":"129","author":"Boil\u00e8ve A","year":"2020","unstructured":"Boil\u00e8ve A, Thomas L, Lillo-Le Lou\u00ebt A, et al.. 5-Fluorouracil-induced hyperammonaemic encephalopathy: a French national survey. Eur J Cancer. 2020, 129:32-40. 10.1016\/j.ejca.2020.01.019","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199903000-00004","article-title":"Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection","volume":"10","author":"Liaw CC","year":"1999","unstructured":"Liaw CC, Wang HM, Wang CH, et al.. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs. 1999, 10:275-81. 10.1097\/00001813-199903000-00004","journal-title":"Anticancer Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01932-w","article-title":"Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study","volume":"26","author":"Okamoto K","year":"2021","unstructured":"Okamoto K, Nozawa H, Hongo K, et al.. Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study. Int J Clin Oncol. 2021, 26:1477-84. 10.1007\/s10147-021-01932-w","journal-title":"Int J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021743","article-title":"Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen: case report","volume":"99","author":"Fukuda M","year":"2020","unstructured":"Fukuda M, Nabeta M, Muta T, et al.. Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen: case report. Medicine (Baltimore). 2020, 99:e21743. 10.1097\/MD.0000000000021743","journal-title":"Medicine (Baltimore)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5414\/CP203747","article-title":"Hyperammonemia-induced impaired consciousness following mFOLFOX6 therapy in a patient with recurrent rectal cancer","volume":"59","author":"Kurokawa T","year":"2021","unstructured":"Kurokawa T, Kanemoto Y, Azuma Y, Iimura Y, Kuroda S, Yazawa K, Tsurita G. Hyperammonemia-induced impaired consciousness following mFOLFOX6 therapy in a patient with recurrent rectal cancer. Int J Clin Pharmacol Ther. 2021, 59:463-6. 10.5414\/CP203747","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2036","article-title":"Hyperammonemia after capecitabine associated with occult impairment of the urea cycle","volume":"8","author":"Chu G","year":"2019","unstructured":"Chu G, Salzman J. Hyperammonemia after capecitabine associated with occult impairment of the urea cycle. Cancer Med. 2019, 8:1996-2004. 10.1002\/cam4.2036","journal-title":"Cancer Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0197-0186(01)00119-x","article-title":"Mitochondrial dysfunction in acute hyperammonemia","volume":"40","author":"Felipo V","year":"2002","unstructured":"Felipo V, Butterworth RF. Mitochondrial dysfunction in acute hyperammonemia. Neurochem Int. 2002, 40:487-91. 10.1016\/s0197-0186(01)00119-x","journal-title":"Neurochem Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-021-01156-6","article-title":"Hyperammonemia in inherited metabolic diseases","volume":"42","author":"Ribas GS","year":"2022","unstructured":"Ribas GS, Lopes FF, Deon M, Vargas CR. Hyperammonemia in inherited metabolic diseases. Cell Mol Neurobiol. 2022, 42:2593-610. 10.1007\/s10571-021-01156-6","journal-title":"Cell Mol Neurobiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04542-7","article-title":"Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database","volume":"92","author":"Oura M","year":"2023","unstructured":"Oura M, Oguro F, Agatsuma N, Imamaki H, Nishikawa Y. Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database. Cancer Chemother Pharmacol. 2023, 92:7-14. 10.1007\/s00280-023-04542-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003278","article-title":"Features of adult hyperammonemia not due to liver failure in the ICU","volume":"46","author":"Sakusic A","year":"2018","unstructured":"Sakusic A, Sabov M, McCambridge AJ, et al.. Features of adult hyperammonemia not due to liver failure in the ICU. Crit Care Med. 2018, 46:e897-903. 10.1097\/CCM.0000000000003278","journal-title":"Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12361","article-title":"Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function: a quantitative modelling study","volume":"34","author":"Noiret L","year":"2014","unstructured":"Noiret L, Baigent S, Jalan R. Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function: a quantitative modelling study. Liver Int. 2014, 34:e45-55. 10.1111\/liv.12361","journal-title":"Liver Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/497629-severe-hyperammonemic-encephalopathy-associated-with-gastrointestinal-bleeding-during-capecitabine-and-oxaliplatin-chemotherapy-in-a-patient-with-rectal-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:21:09Z","timestamp":1779452469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/497629-severe-hyperammonemic-encephalopathy-associated-with-gastrointestinal-bleeding-during-capecitabine-and-oxaliplatin-chemotherapy-in-a-patient-with-rectal-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.109421","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}